cyrilzakka/clinical-trials huggingface dataset:
BDNF Pregnancy Study

The purpose of this study is to evaluate the correlation between varying levels of neuropeptides and birth outcomes. Neuropeptides are substances (proteins) produced in the body in very small amounts but without which the nervous system cannot function properly, and which might have a role in the health of a newborn. As part of this study, we are collecting blood samples from pregnant women.

Neuropeptides and hormones can be measured in blood. This study will involve three blood draws from the participants arm. Demographic information will also be requested, and participants will be asked to complete questionnaires about their mood and personal experiences at each visit.

Our hypothesis is that participants with lower levels of brain-derived neurotrophic factor (BDNF) will be at increased risk for poor birth outcomes.

This prospective, non-randomized trial will evaluate peripheral serum blood levels of BDNF in participants recruited from previously identified University of Pennsylvania obstetrics and gynecological (OB/GYN) clinics. A total of 100 pregnant subjects will be recruited consecutively and evaluated in the first and third trimester of their pregnancy as well as within a month after delivery.

The entire project will take one year.

Eligibility Criteria:
Inclusion Criteria:

* Participants must be at least 18 years old and being treated at an outpatient OB/GYN clinic;
* At least 8 weeks pregnant;
* Capable of giving informed consent.

Exclusion Criteria:

* Participants younger than 18 years of age;
* History of preterm birth;
* Psychiatric medications during current pregnancy;
* Participants with a history of hematologic disorders;
* Participants who refuse informed consent.
Fibromyalgia Therapeutic Education in Thermal Cure

The study evaluates the efficiency, in terms of quality of life improvement, of a patient's therapeutic education program (ETP), based on long term commitment in adapted physical activities carried out during a standardized thermal cure (CTS) for fibromyalgia among patients continuing regular drug treatment or not

Fibromyalgia is a poorly known and understood disease. Patients suffer from pain, fatigue, sleep disorders, anxiety, depression, preventing them from moving and going out, resulting in an alteration of social life. Multiple drugs treatment is frequently used but is burdensome and poorly effective. However, thermal cure proved efficacious to improve quality of life during the cure and beyond. This study aims at demonstrating the added value of a patient's therapeutic education program provided during a thermal cure, a moment where patients are available and receptive to guidance.

Eligibility Criteria:
Inclusion Criteria

* Diagnostic of fibromyalgia done at least 6 months before thermal cure
* Diagnostic of fibromyalgia confirmed by FIRST questionnaire (score 5) during the initial thermal checkup
* Age between 18 and 65 years
* Access to an Internet connection during remote follow-up
* Affiliation to a social security system (recipient or assignee)
* Signed written inform consent form

Exclusion Criteria

* Infectious diseases with ongoing treatment (except for winter upper respiratory tract pathologies)
* Active tumorous pathology
* Concomitant inflammatory rheumatism
* Stage III chronic venous insufficiency with history of phlebitis and/or pulmonary embolism
* Incapacity to receive treatment in hot water ( ≥36°)
* Total incapacity to practice physical activities of therapeutic education program
* Ongoing pregnancy
* Involvement in a structured educational program specific to fibromyalgia during the previous year
* Incapacity to understand French language making the follow up impossible
Effects of Different Protocols of Physical Training on Levels of Muscle Strength and Functional Capacity

Introduction: the peripheral obstructive arterial disease is an condition that affects around 15% of the world population interfering in muscle strength, life quality and functional capacity of patients.

Study aim: to assess three methods of physical training (strength training, aerobic training and electrical stimulation training) in muscle strength, functional capacity and life quality of patients with peripheral obstructive arterial disease

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of PAD and IC.
* Age from 40 to 80 years.
* Stage I and II of Fontaine.
* Symptoms of Intermittent Claudication for at least 3 months with resting brachial index ≤ 0.90 in 1 or 2 legs

Exclusion Criteria:

* Critical ischemia in one of the lower limbs.
* Moderate or severe ulcers in one of the lower limbs. Orthopedic problems that prevent exercise or evaluation.
* Participation in other studies with rehabilitation.
* Decreased arterial hypertension.
* Decompensated Diabetes
Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients

CRRT patients are generally critical ill patients with unstable conditions, such as low blood pressure,severe SIRS,et al. Acute kidney injury(AKI)is especially prevalent,with even two or more organ failure. CRRT serves as an important supportive therapy.Continuous anticoagulation is needed to prevent treatment interruptions due to clotting of the extracorporeal circuit. Unfractionated heparin or low molecular weight heparin both increase the risk of bleeding and heparin induced thrombocytopenia in such cases.However, the problem of CRRT without anticoagulation is the early filter clotting. An alternative method is the use of heparin coated hemofilter. The AN69 ST hemofilter, a surface-treated polyacrylonitrile membrane hemofilter, allows irreversible fixing of heparin to filter membrane, is able to reduce thrombogenic properties of the membrane. In this study, we observe the efficacy and safety of heparin-coated AN69 ST hemofilter in CRRT patients, and compare to the original AN69 membrane hemofilter.


Eligibility Criteria:
Inclusion Criteria:

* Critical ill patients who need continuous renal replacement therapy
* Continuous anticoagulation therapy is not necessarily during CRRT process

Exclusion Criteria:

* Patients needing continuous anticoagulation during each CRRT process
* Expectant survival time less than 72 hours
* Extremely unstable vital signs such as low blood pressure
* Any reasons that resulting in blood flow rate less than 150ml/min
* Pregnant women
* Patients allergic to heparin
Carpal Tunnel Syndrome: Diagnosis and Treatment Trial

The Carpal Tunnel Syndrome Diagnosis and Treatment Trial is project #1 of the Multidisciplinary Clinical Research Center focused on upper extremity pain. It is a randomized trial comparing surgical and nonsurgical treatments for patients with early, mild to moderate carpal tunnel syndrome. In addition the study will evaluate the ability of a new magnetic resonance (MR) technique at predicting who will likely benefit from carpal tunnel syndrome (CTS) surgery.

While there is good evidence that patients with severe CTS benefit from surgery, there is less evidence of a benefit for patients with mild to moderate disease. However, mild to moderate disease still accounts for important disability. Electrodiagnostic studies (EDS) have not been shown to accurately predict outcomes for patients with CTS. Recent advances in MR permit high-resolution neurographic imaging of the median nerve, and pilot data suggest that wrist MRI might be a better predictor of outcome than EDS. Thus, wrist MRI has the potential for playing a major role in the treatment of patients with CTS. We will test two main hypotheses: 1) that select patients with early, mild or moderate CTS benefit more from early surgery than with conservative therapy; and, 2) that wrist MRI accurately identifies those patients more likely to benefit from surgery. We will perform a randomized, controlled treatment trial nested within a prospective cohort as our study design.

Eligibility Criteria:
Inclusion Criteria:

* Paresthesias involving 2 digits on hand diagram
* Willingness and ability to complete interviews

Exclusion Criteria:

* Evidence of denervation on EDS
* Abnormal 2-pt discrimination or thenar atrophy
* Prior wrist surgery or acute external trauma
* MRI contraindications
* Metallic hardware in wrists
Optical Coherence Tomography (OCT) Data Collection Study

Collect OCT data to evaluate the range and age trend of eye measurements.


Eligibility Criteria:
Inclusion Criteria:

* At least 18 years of age
* Able and willing to provide consent
* Able and willing to complete the required examininations and visit
* Refractive error within 8 diopters sphere and within 2 diopters cylinder in each eye
* Best corrected visual acuity of 20/30 or better in each eye

Exclusion Criteria:

* History of leukemia, AIDS, dementia or multiple sclerosis
* Concomitant use of hydroxycloroquine or chloroquine
* Family history of glaucoma among first degree relatives
* Intraocular pressure of 22mm Hg or greater in either eye
* Unreliable or abnormal visual field
* Active ocular disease
* Previously diagnosed with glaucoma or glaucoma suspect
* Congenital ocular abnormalities
* Previous intra-ocular surgery or laser treatment (other than refractive surgery or uncomplicated cataract surgery greater than 6 months previously)
* Anatomic narrow angle
Mandibular Movement Test as a Screening Tool for Polysomnography Candidates

The primary objective of this study is to determine the technical failure and inconclusive test rates when using the Brizzy device for mandibular movement tracking.


Eligibility Criteria:
Inclusion Criteria:

* Patient included in the Brizzy register
* Mandibular movement test prescribed by practitioner
* Patient performed a mandibular movement test (ambulatory setting) using a magnetic sensor (Brizzy, Nomics, Liege, Belgium)

Exclusion Criteria:

* none
Hydration and Outcome in Older Patients

Dehydration is recognised as a major issue in healthcare. Recovery after illness, extended length of stay, pressure sores and slow tissue recovery can all be impacted by dehydration. One of the biggest problems for many people with regard to getting a drink is easy, independent access - if they can't reach the jug/cup without a struggle then they often will go thirsty and potentially become dehydrated.

The purpose of this study is to investigate the impact of dehydration on outcome in patients 65 years and over. Furthermore we aim to assess the impact of providing easy, 24 hour, independently accessible fluids on reducing dehydration as well as improving patient experience.

We hypothesise that patients who are dehydration will take longer to recover from illness and stay in hospital for longer periods.


Eligibility Criteria:
Inclusion Criteria:

1. - All patients of 65 years and over that are admitted acutely to medical wards
2. - Ward staff who have been working in the clinical area for the duration of the trial (The Hydrant part of the study).

Exclusion Criteria:

1. - Patients who are moribund
2. - Patients who are doubly incontinent
3. - Patients on the end of life pathway
4. - Patients with terminal illness with a known life expectancy less than 3 months
Correlation of Different Ultrasonographic Indices With Clinical Parameters in Carpal Tunnel Syndrome

The aim of this study is to investigate the relationship between different ultrasonographic indices used in patients with carpal tunnel syndrome and clinical parameters.

The main questions it aims to answer are:

* To what extent are the ultrasonographic parameters used in the diagnosis of carpal tunnel syndrome related to the patient's clinical complaints?
* To what extent are the different ultrasonographic parameters used in the diagnosis of carpal tunnel syndrome correlated with each other?

Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy and the main mechanism is compression of the median nerve under the transverse ligament at the wrist level. In CTS, neuropathic complaints such as numbness, burning and tingling in the palmar face of the first two fingers, which are the innervation area of the median nerve, and fatigue in the hand are the most common symptoms. In the diagnosis of CTS, the diagnosis is made electrodiagnostically along with typical clinical findings. However, in recent years, ultrasound has become one of the most preferred methods in the diagnosis of CTS because it is non-invasive, rapid and correlates with electrodiagnostic methods. Diameter, cross-sectional area and echogenicity of the median nerve at the carpal tunnel entrance are the most frequently evaluated parameters in ultrasonographic examination. In different studies, it is aimed to increase the power of ultrasonography in the diagnosis of CTS with various indices created in addition to standardized measurements. The most commonly used ultrasonographic indices, which have been shown to be correlated with electrodiagnostic diagnostic methods, are the wrist-forearm median nerve cross-sectional area ratio, the ratio of median nerve cross-sectional area to carpal tunnel area at the carpal tunnel entry level, and echogenicity assessment. Although the relationship of these indexes, which are reported to have sufficient diagnostic sensitivity and specificity, with the patient's clinical complaints is shown on a measurement basis, there is not enough data on the comparison of different formulas and their correlation with the patient's clinical complaints, including neuropathic pain.Based on this, this study aimed to investigate the relationship between ultrasonographic indices used in patients diagnosed with CTS and clinical parameters.

Eligibility Criteria:
Inclusion Criteria:

* Being diagnosed with carpal tunnel syndrome based on clinical and electrodiagnostic findings
* Agreeing to participate in the study

Exclusion Criteria:

* Concomitant history of diabetes, systemic inflammatory disease, active infection and malignancy
* Having a disease with neuropathic pain such as polyneuropathy, radiculopathy,multiple sclerosis
* Not agreeing to participate in the study
* History of surgery due to CTS
Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis

The purpose of this study is to:

1. To evaluate the latest effects of TW for IgA nephropathy (IgAN) with asymptomatic abnormal urinalysis.
2. To evaluate the safety and tolerability of TW.

Patients who fit the inclusion criteria will be randomly divided into three groups: TW group (TW at dosage of 90 mg/d), ARB group (the control group, valsartan at dosage of 160 mg/d) and combined treatment group (TW at dosage of 60 mg/d and valsartan at dosage of 80 mg/d).

Eligibility Criteria:
Inclusion Criteria:

1. 18-60 years old but no requirement for gender
2. All well fit the Diagnostic Criteria for Primary IgAN and IgAN with asymptomatic abnormal urinalysis
3. Informed consent is obtained from each research subject who agrees to conduct a periodic follow-up according to the research arrangement

Exclusion Criteria:

1. Secondary IgA nephropathy, such as Henoch-Schönlein purpura nephritis, Lupus nephritis and so on
2. Some secondary kidney diseases like diabetic nephropathy or other systemic diseases which may effect the pathologic and physiological function of kidney like hypertension and arteriosclerosis
3. Severe infection
4. Abnormality of liver function with glutamic pyruvic transaminase (GPT) or glutamic-oxal(o)acetic transaminase (GOT) more than twice upper limit of normal
5. Women during pregnancy and lactation
6. Patients need to procreation lately
7. Patients treated with TW or ARB within 4 months
Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19

Pilot clinical trial, with a marketed drug -natural component of human plasma-, not approved for this indication, single-center, exploratory, open, randomized, controlled, to study the efficacy and safety of human Antithrombin in patients with confirmed COVID-19 disease and criteria high risk to develop SARS.


Eligibility Criteria:
Inclusion Criteria:

* Age \>= 18 and \< 85 years
* COVID-19 diagnosis confirmed.
* Radiological image compatible with COVID-19
* Present any of the following clinical-functional criteria considered RISK:

  1. Respiratory distress: Tachypnea \> 26 breaths / minute
  2. PaO2 / FiO2 oxygenation index # 300
  3. Alteration of one or more of the following parameters:

  c.i. DD\> 1,000 µg / L c.ii. Ferritin\> 800 ng / mL 4.c.iii. Lymphocytes \<800 cells / µL 4.c.iv. PCR\> 100 mg / L 4.c.v. LDH\> 500 U / L c.vi. IL-6\> 15 pg / mL
* Direct or delegated verbal informed consent

Exclusion Criteria:

* Signs of active bleeding
* Immunosuppression by cancer or transplant
* Intolerance or allergy to AT or its components
* Pregnancy
A Study of Bedaquiline 100 Milligram (mg) Tablets Administered as Different Test Formulations Compared to the Commercial Tablet Formulation (F001) in Healthy Adult Participants

The purpose of this study is to assess the rate and extent of absorption of bedaquiline following administration of a single oral dose of 100 milligram (mg) equivalent (1\*100 mg) given as different test tablet formulations compared to the administration of a single oral dose of 100 mg equivalent (1\*100 mg) formulated as SIRTURO commercial tablet (formulation F001), under fasted conditions in healthy adult participants. Also, to assess the effect of a standardized breakfast on the rate and extent of absorption of bedaquiline compared to fasted conditions following administration of a single oral dose of 100 mg equivalent (1\*100 mg) for each of the different test tablet formulations.


Eligibility Criteria:
Inclusion Criteria:

* A female participant must have a negative highly sensitive serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening and a negative urine pregnancy test on Day -1 in each treatment period
* Contraceptive use by women should be consistent with local regulations regarding the use of contraceptive methods for participant participating in clinical studies
* Participant must have a blood pressure (BP); supine after at least 5 minutes rest) between 90 and 140 millimeter of mercury (mmHg) systolic, extremes included, and no higher than 90 mmHg diastolic at screening
* Participant must be healthy on the basis of physical examination, medical history, vital signs, and electrocardiogram (ECG) performed at screening (results must be available on Day -1). If there are abnormalities participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator
* Participant must have a body mass index (BMI); weight per height square between 18.0 and 30.0 kilogram per meter square (kg/m\^2) (extremes included) at screening. The minimum body weight must be 50.0 kg at screening

Exclusion Criteria:

* Participant with any history of clinically significant skin disease such as, but not limited to, dermatitis, eczema, drug rash, psoriasis, food allergy, or urticaria
* Participant has known allergies, hypersensitivity, or intolerance to bedaquiline or its excipients
* Participant has received an investigational drug or used an invasive investigational medical device within 30 days or within a period less than 10 times the drug's elimination half-life (whichever is longer), or participant has received a biological product within 3 months or within a period less than 5 elimination half-lives (whichever is longer) before the planned first intake of study drug
* Participant has a history of human immunodeficiency virus (HIV)-1 or HIV-2 infection, or tests positive for HIV-1 or -2 at screening
* Participant has previously been dosed with bedaquiline, either in single or multiple dose studies, or participant with a previous history of pulmonal infection with Mycobacterium species
Dexmedetomidine Versus Fentanyl as an Adjuvant to Bupivacaine in Saddle Block

Dexmedetomidine is recommended over fentanyl as adjunctive medication to bupivacaine for saddle block spinal anesthesia in anal surgeries and procedures.

Objectives: A saddle spinal block is a viable choice for anal surgeries. This technique effectively maintains balanced hemodynamics, and fast recovery, and prevents irrelevant motor blocks in both limbs.

Methods: Fifty-eight adult patients were categorized into two groups. Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg). The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml). Continuous monitoring of HR and SpO2 was conducted. Evaluation of sensory blockage and the motor block was done utilizing the Bromage scale. Following surgery, assessments were conducted. Pain in the ward and PACU was determined utilizing the visual analog scale (VAS).

Eligibility Criteria:
Inclusion Criteria:

* both sexes
* aged between 20 and 60
* classified as II \& ASA-I
* scheduled for elective anal surgeries

Exclusion Criteria:

* subjects who refused to participate
* uncontrolled hypertension
* BMI \> 30 kg/m2
* heart failure (class IV or III) based on the New York Heart Association (NYHA)
* uncorrected coagulopathy
* any study's drug allergy
* drug abuse
* neuropathy
* any spinal anesthesia contraindication (such as infection or a pelvic fracture)
Influence of Two Different PEEP Niveaus and a Trendelenburg Positioning Manoeuvre on Subclavian Vein Diameter

In 50 Patients who are undergoing a planned surgical procedure which require a central venous catheter the diameter of the subclavian vein is measured by ultrasound under 6 different conditions.

In 50 Patients who are undergoing a planned surgical procedure which require a central venous catheter the diameter of the subclavian vein is measured by ultrasound under 6 different conditions. The conditions are

1. neutral positioning, PEEP 0 cm H2O,
2. neutral positioning, PEEP 5cm H2O,
3. neutral positioning, PEEP 10cm H2O,
4. Trendelenburg positioning -20°, PEEP 0 cmH2O,
5. Trendelenburg positioning -20°, PEEP 5 cmH2O,
6. Trendelenburg positioning -20°, PEEP 10 cmH2O After these measurements a central venous catheter is used to measure the central venous pressure.

Eligibility Criteria:
Inclusion Criteria:

* Age \>18 years
* cardiosurgery or neurosurgery
* written informed consent
* ECG: inus rhythm

Exclusion Criteria:

* peacemaker
* kontraindications for PEEP
* pulmonary disease
* hemodynamically instable patients
* pregnancy
* pulmonal Hypertension
* ejection fraction \< 35%
* severe valvular disease
* tricuspid insufficiency